• Publications
  • Influence
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison
UNLABELLED One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet limited data exist on its prevalence in US patients with schizophrenia. METHODS Using baselineExpand
  • 1,018
  • 54
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
OBJECTIVE The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, includingExpand
  • 628
  • 32
  • PDF
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
UNLABELLED Persons diagnosed with schizophrenia have higher morbidity and mortality rates from cardiovascular disease, yet often have limited access to appropriate primary care screening orExpand
  • 488
  • 30
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
  • D. Goff, J. Coyle
  • Medicine, Psychology
  • The American journal of psychiatry
  • 1 September 2001
OBJECTIVE Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia. This review evaluates evidence from preclinical and clinical studies thatExpand
  • 827
  • 24
  • PDF
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
OBJECTIVE Standardized mortality rates are elevated in schizophrenia compared to the general population. The incidence of coronary heart disease (CHD) and the relative contribution of CHD toExpand
  • 458
  • 21
Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
OBJECTIVE Tardive dyskinesia is a movement disorder affecting 20%-40% of patients treated chronically with neuroleptic drugs. The dopamine supersensitivity hypothesis cannot account for the timeExpand
  • 215
  • 18
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
OBJECTIVE The authors' goal was to study the relationship between smoking status and clinical characteristics in schizophrenic patients. METHOD Seventy-eight schizophrenic outpatients were assessedExpand
  • 550
  • 17
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome
UNLABELLED The metabolic syndrome (MS) is highly prevalent among patients with schizophrenia (current estimates 35-40%), yet no data exist on the correlation of this diagnosis with illness severity,Expand
  • 184
  • 17
Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia
INTRODUCTION Patients with schizophrenia show deficits in facial affect and facial identity recognition and exhibit structural and neurophysiological abnormalities in brain regions known to mediateExpand
  • 215
  • 17
The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls
Abundant evidence indicates that the neuronal nicotinic acetylcholine receptor (nAChR) system is integral to regulation of attentional processes and is dysregulated in schizophrenia. NicotinicExpand
  • 212
  • 15